GeneDx Holdings Corp. (WGS) is a Medical/Nursing Services company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for WGS, including 3 press releases and news items, 1 earnings update and 1 13D/G filing. The most recent was published Nov 6, 2026.
WGS rankings
Financial highlights
Full financials- Revenue, TTM
- $454.43M
- Revenue growth
- +25.4%
- Net income, TTM
- -$106.36M
- Net margin
- -23.4%
- Free cash flow, TTM
- -$75.80M
- Cash
- $60.32M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks470%
2026-05-102026-11-01
Mix1990d
- Other10(53%)
- Insider6(32%)
- SEC Filings1(5%)
- Earnings1(5%)
- 13D/G1(5%)
Activity · 52 weeks10165 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GSEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.SCHEDULE 13G - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic TestingCollaboration provides no-cost exome testing for eligible patients with unexplained cholestasis, early-onset cataracts, or suspected or confirmed PBD-ZSD GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a collaboration with Mirum Pharmaceuticals to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisomal biogenesis disorder–Zellweger spectrum disorders (PBD-ZSD). Across these programs and for patients that meet specific criteria, GeneDx and Mirum are addressing a shared challenge in rare disease care: helping identify the genetic cause o
- PRGeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx’s (NASDAQ:WGS) mission
- PRGeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisGeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-
- PRGeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx-led platform presentation explores machine learning to prioritize relevant copy numb
- PRGeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026New GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families Data from BRIDGES-NBS shows an expert-informed approach to broadening the number of actionable conditions appropriate for gNBS GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented at the International Consortium on Newborn Sequencing (ICoNS), October 7-8 in Boston, demonstrating progress toward making genomic newborn screening (gNBS) a scalable and accessible part of proactive healthcare. As a sequencing and inter
- PRGeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric CareNew tools make genomic testing easier from ordering through results, helping pediatricians confidently integrate genomics into routine care GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will introduce Easy Order at the 2026 American Academy of Pediatrics (AAP) National Conference & Exhibition, October 2-6 in San Diego. The new streamlined experience makes it faster and simpler for general pediatricians to order ExomeDx™ and chromosomal microarray (CMA) and is part of GeneDx’s broader effort to simplify genomic testing from ordering through understanding and communicating results. In 2025, the AAP updated its guida
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Fuchs Thomas converted options into 1,146 shares (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 6,547 shares and sold $310,932 worth of shares (3,692 units at $84.22), increasing direct ownership by 3% to 107,227 units (SEC Form 4) to cover taxes4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 2,462 shares and sold $108,220 worth of shares (1,285 units at $84.22), increasing direct ownership by 3% to 41,476 units (SEC Form 4) to satisfy tax liability4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- PRGeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type CNPC GenomeComplete to identify children who might otherwise remain undiagnosed through broad NPC-specific eligibility criteria, comprehensive genomic testing and expert diagnostic support GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a collaboration with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program. The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address barriers to diagnosis and identify children who are currently und
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $31,188 worth of shares (372 units at $83.84), increasing direct ownership by 0.86% to 40,299 units (SEC Form 4) to cover taxes4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECSEC Form 144 filed by GeneDx Holdings Corp.144 - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 HonoreeRecognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901577181/en/ "What makes this recognition so meanin
- PRGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’sPublished in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis Children experiencing faltering growth saw striking 63% diagnostic yield GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data published in Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), in collaboration with the clinical genetics team at Seattle Children’s. The study demonstrates that implementing first-tier rapid genome sequencing (rGS) broadly across inpatient pediatri
- SECSEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.SCHEDULE 13G - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and EpilepsyNew offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy. Families can now initiate a genetic test directly from GeneDx.com, providing underserved children and families who face barriers to local specialty care with a faster path to c
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.SCHEDULE 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx to Participate in Upcoming Investor ConferencesGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity 46th Annual Growth Conference Boston, MA Fireside Chat: Tuesday, August 11 at 11:00 a.m. ET Wells Fargo 21st Annual Healthcare Conference Boston, MA Fireside Chat: Tuesday, September 8 at 2:15 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx’s (NASDAQ:WGS) mission is to empower everyone to live their healthi
- SECSEC Form 10-Q filed by GeneDx Holdings Corp.10-Q - GeneDx Holdings Corp. (0001818331) (Filer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx Reports Second Quarter 2026 Financial ResultsReported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30% Hosting conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026. "Our team’s unwavering focus and agility drove a strong second
- SECSEC Form 25-NSE filed by GeneDx Holdings Corp.25-NSE - GeneDx Holdings Corp. (0001818331) (Subject)
WGS FAQ
10 questionsWhat is the latest news on WGS?
In the last 30 days Quantisnow tracked 5 wire items for WGS: 3 press releases and news items, 1 earnings update and 1 13D/G filing. The most recent was published on November 6, 2026.What is WGS revenue?
GeneDx Holdings Corp. (WGS) reported $454.43M of revenue for the twelve months ended Jun 30, 2026. That is up 25.4% from the year before. Revenue for fiscal 2025 was $427.54M.Is WGS profitable?
No. GeneDx Holdings Corp. reported a net loss of $106.36M for the twelve months ended Jun 30, 2026.How much cash and debt does WGS have?
GeneDx Holdings Corp. reported $60.32M in cash and cash equivalents and $96.84M of debt on its most recent balance sheet in SEC filings.Where does WGS stock trade?
GeneDx Holdings Corp. (WGS) is listed on NASDAQ.What sector and industry is WGS in?
GeneDx Holdings Corp. operates in the Health Care sector, Medical/Nursing Services industry.When did GeneDx Holdings Corp. go public?
GeneDx Holdings Corp. (WGS) completed its IPO in 2020.What are analysts saying about WGS?
Across the last 8 analyst actions on GeneDx Holdings Corp., there were 2 upgrades and 0 downgrades. The most recent action was from Wells Fargo: Overweight with a $155.00 price target on 2026-02-09.What companies are similar to WGS?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), CHE (Chemed Corp), HIMS (Hims & Hers Health Inc.), LFST (LifeStance Health Group Inc.), OPCH (Option Care Health Inc.). Compare WGS side-by-side with any of them on Quantisnow.How can I track WGS on Quantisnow?
Quantisnow aggregates GeneDx Holdings Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WGS to receive live email and push alerts on every new disclosure.